Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Pearce IP BioBlast™: w/e 27 November 2020

by , | Dec 1, 2020

22 Nov 20 | Innovent released results of Ph III trials of Tyvyt® (sintilimab) with Byvasda® (biosimilar bevacizumab) as first-line treatment in patients with Advanced Hepatocellular Carcinoma (HCC).

24 Nov 20 | EU | The EMA approved Pfizer’s Nyvepria® (biosimilar pegfilgrastim).

24 Nov 20 | CA | BGP Pharma received a NOC from Health Canada for Hulio® (biosimilar adalimumab).

24 Nov 20 | CN | Alvotech and Alvotech & CCHT Biopharmaceutical announced they have partnered with Yangtze River Pharmaceutical Group to form an exclusive strategic partnership for the commercialisation of eight biosimilar medicines in China.  Alvotech and Alvotech & CCHT will be jointly responsible for the development, registration, and supply of biosimilars in China, while Yangtze River Pharmaceutical will exclusively commercialise them.  The products will be manufactured in a new biopharmaceutical facility currently being built in Changchun, China through the Alvotech & CCHT partnership.

25 Nov 20 | EU | Bio-Thera Solutions announced it has submitted a marketing authorisation application for BAT1706 (proposed bevacizumab biosimilar) in EU.

26 Nov 20 | The Centre for Biosimilars reported on Alvotech’s global biosimilar strategy. Dr Joseph McClellan, Alvotech’s Chief Scientific Officer commented on Alvotech’s long-term expansion plans for global biosimilars markets, suggesting that Alvotech will obtain regulatory approvals for multiple products almost simultaneously in multiple countries before launching.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News